- Ukwelashwa
- Ubufakazi
- I-Neuroblastoma
- Isimila Esiqinile
- Ubufakazi
- I-TILS
- Ukwelashwa Kwamaseli e-NK
- I-Myasthenia Gravis (MG)
- I-Acute Lymphoblastic Leukemia (B-ALL)
- I-Systemic Lupus Erythematosus (SLE)
- I-Acute Lymphoblastic Leukemia (T-ALL)
- I-Non-Hodgkin Lymphoma (NHL)
- I-Multiple Myeloma (MM)
- I-Diffuse Large B-cell Lymphom
- I-B-lymphocytic Leukemia
- I-Myeloma
Ukwelashwa kwe-CAR-T kwe-Multiple Myeloma (MM)
Ukubuka konke
I-Multiple Myeloma (MM) uhlobo lomdlavuza oluthinta amangqamuzana e-plasma emnkantsheni wamathambo. Yaziwa ngesimo sayo esiyinkimbinkimbi nesiguquguqukayo, okuvame ukuholela ekubuyeleni emuva kanye nokumelana nemithi yendabuko. Nakuba ukwelashwa ngamakhemikhali, ukufakelwa kwamangqamuzana e-stem, kanye nemithi emisha kube nemiphumela ethuthukisiwe, iziguli eziningi ekugcineni zibhekene nokumelana nokwelashwa. Ukwelashwa kwe-CAR-T (Chimeric Antigen Receptor T-cell) kuyindlela yokwelapha entsha eye yabonisa impumelelo emangalisayo ekwelapheni i-multiple myeloma ebuyele emuva futhi engaphikisi, enikeza ikhambi elithembisayo ezigulini ezinezinketho ezilinganiselwe.
Kuyini Ukwelashwa kwe-CAR-T kwe-MM?
Ukwelashwa kwe-CAR-T kuhilela ukuguqula amaseli e-T esiguli ukuze aqaphele futhi ahlasele kangcono amaseli omdlavuza. Kuma-myeloma amaningi, amaseli e-CAR-T aklanywe ukuze aqondise i-BCMA (i-B-cell maturation antigen), iphrotheni etholakala ebusweni bamaseli e-myeloma. Ngemva kokuguqulwa kwezakhi zofuzo, lawa maseli e-T afakwa emzimbeni wesiguli, lapho efuna khona futhi abhubhise amaseli anomdlavuza, okungenzeka kuholele ekukhululweni nasekusindeni isikhathi eside.
Izinzuzo Eziyinhloko Zokwelashwa Kwe-CAR-T Kwe-Multiple Myeloma
- Ukusebenza Okuphezulu ku-MM Ebuyiselwe/EngaguqukiUkwelashwa kwe-CAR-T kubonise impumelelo enkulu ezigulini ezine-myeloma ephindaphindayo noma engaphikisi, ngokuvamile kufinyelela ekukhululweni okuphelele noma isimo se-minimum residual disease (MRD).
- Ukunemba Okuqondiwe: Ngokugxila ku-BCMA, ukwelashwa kwe-CAR-T kuhlasela ngqo amangqamuzana e-myeloma, kusindisa izicubu ezinempilo futhi kunciphisa imiphumela emibi uma kuqhathaniswa nokwelashwa okuvamile.
- Kwenziwe Ngokwezifiso Futhi Kunobusha: Ukwelashwa kusebenzisa amaseli e-T esiguli, okuqinisekisa uhlelo lokwelashwa oluqondene nomuntu siqu. Lokhu kusiza futhi ukunciphisa ingozi yokwenqatshwa.
- Ukuxolelwa Kwesikhathi EsideIziguli eziningi ezelashwa ngokwelashwa kwe-CAR-T zithola izimpendulo ezihlala isikhathi eside, kanti ezinye zigcina ukuphulukiswa iminyaka eminingi, ngisho nangemva kokuba ezinye izindlela zokwelapha zehlulekile.
Inqubo Yokwelapha
- Ukuqoqwa kwamaseli e-TIsinyathelo sokuqala sihilela ukuqoqa amaseli e-T egazini lesiguli kusetshenziswa i-leukapheresis, inqubo efana nokunikela ngegazi.
- Ubunjiniyela bamaseli e-T: Lawa ma-T-cell abe esethunyelwa elabhorethri, lapho aguqulwa khona izakhi zofuzo ukuze aveze i-CAR ethize ku-BCMA, okuthuthukisa ikhono lawo lokubona nokubulala amaseli e-myeloma.
- Ukufakwa Kwamaseli E-CAR-TNgemva kokwandiswa elabhorethri, ama-T-cell aklanywe ngendlela ethuthukisiwe aphinde afakwe egazini lesiguli nge-IV.
- Ukuqapha Nokubuyisela Esimeni: Ngemva kokufakwa, iziguli ziqashwe ngeso lokhozi imiphumela emibi engaba khona njenge-cytokine release syndrome (CRS) noma ubuthi be-neurotoxicity. Le miphumela emibi ivame ukuphathwa ngokungenelela kwezokwelapha kanye nokuqapha.
Kungani Kufanele Ukhethe Ukwelashwa Kwe-CAR-T Kwe-BIOOCUS Kwe-Multiple Myeloma?
- Ubuchwepheshe be-CAR-T obusezingeni eliphezuluI-BIOOCUS isebenzisa intuthuko yakamuva kubuchwepheshe be-CAR-T ukuqinisekisa ukwelashwa kwekhwalithi ephezulu kanye nemiphumela emihle kakhulu yeziguli ze-MM.
- Ubuchwepheshe Bezokwelapha Bezinga Lomhlaba WonkeIthimba lethu lochwepheshe kwezokwelapha ngegazi kanye ne-immunotherapy linikeza ukunakekelwa komuntu siqu, ukuqinisekisa ukuthi isiguli ngasinye sithola ukwelashwa okungcono kakhulu ngesimo saso esiyingqayizivele.
- Irekhodi Eliqinisekisiwe Lethrekhi: Selaphe iziguli eziningi ze-MM ngokwelashwa kwe-CAR-T, futhi eziningi ziye zathola ukuphulukiswa okuphawulekayo nokuhlala isikhathi eside.
- Ukusekelwa Okuphelele Kweziguli Zamazwe Ngamazwe: I-BIOOCUS inikeza ukwesekwa okugcwele kweziguli zamazwe ngamazwe, ikuqondisa kuzo zonke izinyathelo zenqubo yokwelashwa, kusukela ekubonisaneni kokuqala kuya ekunakekelweni kwangemva kokwelashwa.
Ubufakazi Bezokwelapha kanye Namazinga Empumelelo
-
Ubufakazi Bezokwelapha kanye Namazinga Empumelelo
Ukwelashwa kwe-CAR-T kwe-multiple myeloma kubonise imiphumela emihle kakhulu ezivivinyweni zemitholampilo nasezindaweni zangempela. Ikakhulukazi, kuye kwabonakala kusebenza kahle ezigulini eziphinde zabuyela emuva ngemva kwemigqa eminingi yokwelashwa, kanti ezinye zifinyelela ukuphulukiswa okuphelele noma isimo sokungalungi kwe-MRD.
- Indaba Yesiguli: Ukufinyelela Ukukhululwa Kwesikhathi Eside nge-CAR-T ye-Multiple Myeloma
- Ucwaningo Lwecala: Impendulo Ephelele Ngemva Kokwelashwa Kwe-CAR-T Ku-Relapsed Multiple Myeloma
- Ukusebenza Kokwelashwa Kwe-CAR-T Ekwelapheni I-Myeloma Ephindaphindekile/Engaphenduli
Lezi zifundo zibonisa indlela ukwelashwa kwe-CAR-T okuguqula ngayo isimo sokwelashwa kwe-multiple myeloma, okunikeza iziguli ithemba lokusinda isikhathi eside kanye nekhwalithi yokuphila ethuthukisiwe.
Idatha Yezokwelapha
Izinkomba ze-CD19+20CAR-T:Iziguli ezine-B-cell non-Hodgkin's lymphoma
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 71.95% (59/82) | 25.6（21/82） | 97.55（80/82） | 12.19% (10/82) | 0 |
Izinkomba ze-CD19+22CAR-T:Ukwelashwa kweziguli ezine-CD19 eziphinde zabuyela emuva futhi ezingasabeli kahle i-B-lymphocytic leukemia
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 92.1%（35/38） | 7.9%（3/38） | 100% (38/38) | 15.79% (6/38) | 0 |
Izinkomba ze-BCMACAR-T:Ukwelashwa kwe-myeloma eminingi ephinde yabuya futhi engaphikisi
| Izinga le-CR lenyanga eyodwa | Izinga le-PR lenyanga eyodwa | Isilinganiso se-OR senyanga eyodwa | I-CRS≥3 | I-CRES≥3 |
| 72.41% (21/29) | 27.59%（8/29） | 100% (29/29) | 6.9% (2/29) | 0 |
Submit An Free Inquiry
Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.